Popular Articles

Women's First-trimester Working Conditions Impact Infant Birthweight
A new study shows that high levels of job strain during early pregnancy are associated with reduced birthweight and an increased risk of delivering a small-for-gestational-age (SGA) infant.
generic viagra
Sexual Crimes: Narrow Window For Detection Of Knock-Out Drugs
Drug-facilitated sexual crimes are increasing. The Bonn Institute for Forensic Medicine has recorded that the number of examinations on the use of intoxicants in sexual offences within their catchment area increased 10-fold between 1997 and 2006. In the current edition of Deutsches Arzteblatt International, Burkhard Madea and Frank Musshoff present the modes of action and the detection windows for the most frequent substances (Dtsch Arztebl Int 2009; 106 (20): 341-347).
Zubni implantati
News of the day
FOCUS On FOCIS: Combined Chemo-Immunotherapy For The Treatment Of Hormone-Refractory Metastatic Prostate Cancer
UroToday.com - The long-term goal of the Tumor Immunology and Immunotherapy group at The Institute of Immunology, Charles University, 2nd Medical School is the development of dendritic cell-based cancer vaccine. Administration of this vaccine will induce the tumor cell-specific induce response, complement current treatment modalities, and contribute to an improved prognosis of patients with cancer.
Medical Devices

Important Modulator Of Immune Cell Entry Into The Brain Discovered

Researchers in Berlin, Germany have ameliorated inflammation of the brain in mice caused by immune cells. A receptor they discovered on the surface of T cells in the central nervous system (CNS) plays the key role. The researchers showed that this bradykinin receptor 1 (B1) controls the infiltration of immune cells into the CNS. When they activated B1 in mice with encephalitis, they were able to slow down the crossing of the immune cells through the blood-brain-barrier into the CNS. As a result, the inflammation markedly decreased. Commenting on the findings, Helen Yates, Multiple Sclerosis Re Centre Chief Executive said, "This is a very important piece of research. We have long known that the crossing of immune cells into the CNS is a major problem in MS. This work shows that inflammation can be decreased and hopefully will lead to further research into prevention of the inflammatory response completely." The work by Dr. Ulf Schulze-Topphoff, Prof. Orhan Aktas, and Professor Frauke Zipp (Cecilie Vogt-Clinic, Charité - Universitätsmedizin Berlin, Max DelbrÃøck Center for Molecular Medicine (MDC) Berlin-Buch and NeuroCure Research Center) together with researchers in Canada and the USA may unveil a new target for the treatment of chronic inflammatory diseases such as multiple sclerosis (MS) (Nature Medicine, doi 10.1038/nm.1980)*. It has been known for a long time that T cells can attack the body"s own structures and, if they infiltrate the CNS, cause diseases such as multiple sclerosis (MS). The T cells damage the myelin sheath, the material that surrounds and protects the fibers of nerve cells. This damage slows down or blocks messages between the brain and the body, leading to various symptoms of MS such as impaired movements. The molecular analysis of damaged tissue from patients with MS led the researchers to the B1-receptor. The data they evaluated showed that two different pathways known to play a crucial role in the cardiovascular area also seem to play an important role in the CNS: namely, the renin-angiotensin-system, and the kallikrein-kinin-system, the latter of which the researchers in Berlin put their focus on. The B1-receptor is part of the kallikrein-kinin-system. Together with Professor Alexandre Prat from the Université de Montréal, Montréal, Canada, and Professor Lawrence Steinman from Stanford University in Stanford, California, USA, the researchers in Berlin detected the B1-receptor on T cells of MS patients as well as on T cells of mice with encephalitis, an inflammation of the brain. The disease got worse in those mice that lacked B1 on their T cells. Therefore, using a certain substance (Sar-[D-Phe]desArg9-bradykinin), they activated the receptor in mice which had B1 on their T cells. As a result, the entry of T cells into the CNS slowed down and the clinical symptoms of the inflammation markedly decreased. "We have discovered a control mechanism, which reduces inflammation caused by the immune system" neurologist and MDC research group leader Professor Zipp explains. "It remains to be seen if we succeed in developing a new therapy for chronic inflammation in the CNS, such as MS, in the future." Multiple Sclerosis Re Centre


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):